Dobiásová M, Frohlich J
Fyziologický ústav Akademie vĕd Ceské republiky, Praha.
Vnitr Lek. 2000 Mar;46(3):152-6.
The new atherogenic plasma index (AIP) is a logarithmic transformation of the ratio of the molar triglyceride (TG) concentration and high density lipoprotein cholesterol (HDL-C). AIP correlates closely with the size of LDL particles (r = 0.8) and esterification rate of plasma cholesterol devoid of apo B lipoproteins (FERHDL), r = 0.9 which are considered at present the most sensitive indicators of the atherogenic plasma profile. AIP was recommended by the authors, based on analysis of results of 11 previous studies (1156 subjects) where FERHDL and plasma lipid parameters were investigated in different groups of people who differed as to the atherogenic risk. The AIP index was moreover used for evaluation of a clinical study comprising 609 patients with hyperlipidaemia, who were treated for three months with ciprofibrate (Lipanor). The mean AIP values of non-risk groups (plasma from umbilical blood, children, healthy women etc.) equalled zero or were lower, while with an increasing atherogenic risk (men, women after the menopause) AIP reached positive values, incl. high positive values in risk groups (plasma of diabetic subjects, patients with HLP, patients with positive angiography, myocardial infarction etc.). In all groups women had lower AIP values as compared with males. In patients after Lipanor therapy the AIP declined (from 0.58 +/- 0.17 to 0.33_0.18 in men, from 0.50 +/- 0.18 to 0.21 +/- 0.19 in women). If we consider AIP values from negative ones to 0.15 as "safe" from the aspect of atherogenicity, before Lipanor treatment these "safe" levels were recorded in 1.5% men and in 5.2% women and after treatment in 32% men and 48% women. The results indicate, that AIP which reflects the plasma lipoprotein profile quantifies the relations between TG and HDL-C and thus can be an objective indicator of the atherogenic risk and effectiveness of treatment and it is useful because it can be assessed in any surgery.
新的致动脉粥样硬化血浆指数（AIP）是甘油三酯（TG）摩尔浓度与高密度脂蛋白胆固醇（HDL-C）比值的对数转换。AIP与低密度脂蛋白颗粒大小（r = 0.8）以及不含载脂蛋白B的血浆胆固醇酯化率（FERHDL）密切相关，r = 0.9，目前认为这是致动脉粥样硬化血浆谱最敏感的指标。作者根据对之前11项研究（1156名受试者）结果的分析推荐了AIP，这些研究在不同致动脉粥样硬化风险的人群组中对FERHDL和血脂参数进行了调查。此外，AIP指数还用于评估一项包含609例高脂血症患者的临床研究，这些患者接受环丙贝特（Lipanor）治疗三个月。非风险组（脐血、儿童、健康女性等的血浆）的平均AIP值等于零或更低，而随着致动脉粥样硬化风险增加（男性、绝经后女性），AIP达到正值，包括风险组（糖尿病患者、高脂血症患者、血管造影阳性患者、心肌梗死患者等的血浆）中的高正值。在所有组中，女性的AIP值均低于男性。接受Lipanor治疗的患者AIP下降（男性从0.58±0.17降至0.33_0.18，女性从0.50±0.18降至0.21±0.19）。如果从致动脉粥样硬化性的角度将AIP值从负值到0.15视为“安全”，在Lipanor治疗前，这些“安全”水平在1.5%的男性和5.2%的女性中记录到，治疗后在32%的男性和48%的女性中记录到。结果表明，反映血浆脂蛋白谱的AIP量化了TG与HDL-C之间的关系，因此可以作为致动脉粥样硬化风险和治疗效果的客观指标，并且由于它可以在任何手术中进行评估，所以很有用。
